Trial · NCT05323656
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 12 Months | 46 | 80% Confidence Interval 19.4 to 72.5 | percentage of participants |
| Overall Survival (OS) | Placebo and Pembrolizumab 200 mg | 12 Months | 42 | 80% Confidence Interval 26.0 to 58.2 | percentage of participants |
| Number of Participants With Adverse Events (AEs) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 27 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Placebo and Pembrolizumab 200 mg | 26 | Participants | ||
| Number of Participants With Adverse Events of Special Interest (AESI) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 5 | Participants | ||
| Number of Participants With Adverse Events of Special Interest (AESI) | Placebo and Pembrolizumab 200 mg | 5 | Participants | ||
| Levels of Programmed Death-ligand 1 (PD-L1) Expression in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Baseline | 19.73 | Standard Deviation 29.408 | ratio |
| Levels of Programmed Death-ligand 1 (PD-L1) Expression in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Baseline | 13.14 | Standard Deviation 25.149 | ratio |
| Levels of Programmed Death-ligand 1 (PD-L1) Expression in Tumour Tissue | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 42.27 | Standard Deviation 37.641 | ratio |
| Levels of Programmed Death-ligand 1 (PD-L1) Expression in Tumour Tissue | Placebo and Pembrolizumab 200 mg | Week 9 | 18.57 | Standard Deviation 15.999 | ratio |
| Change From Baseline in CAFs Cell Type Abundance Based on Gene Expression Profiles | Setanaxib 1600 mg and Pembrolizumab 200 mg | Screening | 0.87 | Standard Deviation 0.880 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CAFs Cell Type Abundance Based on Gene Expression Profiles | Placebo and Pembrolizumab 200 mg | Screening | 0.74 | Standard Deviation 0.787 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CAFs Cell Type Abundance Based on Gene Expression Profiles | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 0.98 | Standard Deviation 0.990 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CAFs Cell Type Abundance Based on Gene Expression Profiles | Placebo and Pembrolizumab 200 mg | Week 9 | 0.56 | Standard Deviation 0.581 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CD8+ TILs Cell Type Abundance Based on Gene Expression Profiles | Setanaxib 1600 mg and Pembrolizumab 200 mg | Screening | 0.03 | Standard Deviation 0.030 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CD8+ TILs Cell Type Abundance Based on Gene Expression Profiles | Placebo and Pembrolizumab 200 mg | Screening | 0.04 | Standard Deviation 0.044 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CD8+ TILs Cell Type Abundance Based on Gene Expression Profiles | Setanaxib 1600 mg and Pembrolizumab 200 mg | Week 9 | 0.07 | Standard Deviation 0.063 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in CD8+ TILs Cell Type Abundance Based on Gene Expression Profiles | Placebo and Pembrolizumab 200 mg | Week 9 | 0.02 | Standard Deviation 0.033 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in Regulatory T-cell Abundance Based on Gene Expression Profiles | Setanaxib 1600 mg and Pembrolizumab 200 mg | Screening | 0.01 | Standard Deviation 0.012 | CIBERSORTx Absolute Abundance ratio |
| Change From Baseline in Regulatory T-cell Abundance Based on Gene Expression Profiles | Placebo and Pembrolizumab 200 mg | Screening | 0.02 | Standard Deviation 0.033 | CIBERSORTx Absolute Abundance ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/results?page=3